Simultaneous Integrated Boost Irradiation After Breast-Conserving Surgery: Physician-Rated Toxicity and Cosmetic Outcome at 30 Months’ Follow-Up  by Bantema-Joppe, Enja J. et al.
International Journal of
Radiation Oncology
biology physics
www.redjournal.orgClinical Investigation: Breast Cancer
Simultaneous Integrated Boost Irradiation After
Breast-Conserving Surgery: Physician-Rated Toxicity
and Cosmetic Outcome at 30 Months’ Follow-Up
Enja J. Bantema-Joppe, M.D.,* Cornelis Schilstra, Ph.D.,*
Geertruida H. de Bock, Ph.D.,y Wil V. Dolsma, M.D., Ph.D.,* Dianne M. Busz, M.D.,*
Johannes A. Langendijk, M.D., Ph.D.,* and John H. Maduro, M.D., Ph.D.*
Departments of *Radiation Oncology and yEpidemiology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands
Received Jun 13, 2011, and in revised form Jan 14, 2012. Accepted for publication Jan 16, 2012Summary
Three-dimensional conformal
radiotherapy with a hypo-
fractionated, simultaneous
integrated boost (3D-CRT-
SIB) can be used as part of
breast-conserving therapy. In
this prospective study of 940
patients treated with 3D-CRT-
SIB, cosmetic outcome (CO)
and toxicity were assessed
until 5 years after radiotherapy.
Toxicity and CO were not
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Open access undPurpose: To evaluate toxicity and cosmetic outcome (CO) in breast cancer survivors treated with
three-dimensional conformal radiotherapy with a hypofractionated, simultaneous integrated boost
(3D-CRT-SIB) and to identify risk factors for toxicity, with special focus on the impact of age.
Methods and Materials: Included were 940 consecutive disease-free patients treated for breast
cancer (Stage 0eIII) with 3D-CRT-SIB, after breast-conserving surgery, from 2005 to 2010.
Physician-rated toxicity (Common Terminology Criteria for Adverse Events version 3.0) and
CO were prospectively assessed during yearly follow-up, up to 5 years after radiotherapy. Multi-
variate logistic regression analyses using a bootstrapping method were performed.
Results: At 3 years, toxicity scores of 436 patients were available. Grade2 fibrosis in the boost
area was observed in 8.5%, non-boost fibrosis in 49.4%, pain to the chest wall in 6.7%, and fair/
poor CO in 39.7% of cases. Radiotherapy before chemotherapy was significantly associated with
grade 2 boost fibrosis at 3 years (odds ratio [OR] 2.8, 95% confidence interval [CI] 1.3e6.0).
Non-boost fibrosis was associated with re-resection (OR 2.2, 95% CI 1.2e4.0) and larger tumors
(OR 1.1, 95% CI 1.0e1.1). At 1 year, chest wall pain was significantly associated with high boost
dosage (OR 2.1, 95%CI 1.2e3.7) and younger age (OR 0.4, 95%CI 0.2e0.7). A fair/poor COwas
observedmore often after re-resection (OR 4.5, 95% CI 2.4e8.5), after regional radiotherapy (OR
2.9, 95% CI 1.2e7.1), and in larger tumors (OR 1.1, 95% CI 1.0e1.1).
Conclusions: Toxicity and CO are not impaired after 3D-CRT-SIB. Fibrosis was not significantly
associated with radiotherapy parameters. Independent risk factors for fibrosis were chemotherapy
after radiotherapy, re-resection, and larger tumor size. Re-resection was most predictive for worse
CO. Age had an impact on chest wall pain occurrence.
 2012 Elsevier Inc.
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Table 1 Patient characteristics (n Z 940)
Characteristic n %
Age at start of RT (y)
50 214 22.8
>50 726 77.2
Location
Lateral 496 52.8
Medial 186 19.8
Rest 204 21.7
Missing 54 5.7
Pathological T stage
pT in situ 35 3.7
pT1 672 71.5
pT 2 233 24.8
Pathologic N stage
pN0 655 69.7
pNþ 255 27.1
pNx 30 3.2
Re-resection
No 831 88.4
Yes 109 11.6
Axillary clearance
No 656 69.8
Yes 284 30.2
Adjuvant chemotherapy
No 602 64.0
Yes 338 36.0
Adjuvant hormonal therapy
No 551 58.6
Yes 389 41.4
Adjuvant trastuzumab
No 901 95.9
Yes 39 4.1
Regional RT
No 880 93.6
Yes 60 6.4
Treatment sequence
Surgery-RT 602 64.0
RT-chemotherapy 155 16.5
Chemotherapy-RT 183 19.5
Boost tumor bed
Low (64.4 Gy) 705 75.0
High (67.2 Gy) 235 25.0
Smoking
No 770 81.9
Yes 170 18.1
Abbreviation: RT Z radiotherapy.
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Breast-conserving therapy (BCT), consisting of breast-conserving
surgery followed by radiotherapy (RT), is considered the standard
of care for early-stage breast cancer (1). In BCT, whole-breast
irradiation with the addition of a boost to the tumor bed reduces
the risk of local recurrence in invasive breast cancer (2).
Since 2005, in our department, patients undergoing breast-
conserving surgery are irradiated with three-dimensional conformal
RT with a simultaneous integrated photon boost (3D-CRT-SIB), as
previously described (3). Compared with sequential boost tech-
niques, 3D-CRT-SIB provides increased dose homogeneity, with less
unintended excessive dose outside the boost area, in combination
with a higher dose per fraction to the tumor bed, resulting in a shorter
overall treatment time. Acute toxicity is relatively mild (3). With the
3D-CRT-SIB technique, the daily fraction to the boost area is 2.3 or
2.4 Gy. Because of the higher dose per fraction, there might be an
increased risk of fibrosis and subsequent impaired cosmetic outcome
(CO). The first results on clinical outcome are excellent, with a 3-year
local control rate of 99.6% (4). Yet there are no data on toxicity and
CO after this hypofractionated 3D-CRT-SIB technique.
The primary aim of the present study was to evaluate
physician-rated toxicity and CO in a series of early-stage breast
cancer patients treated with 3D-CRT-SIB at a median of 30
months of follow-up. In addition, we tried to identify prognostic
factors for toxicity and CO, with special focus on the impact of
age on the risk of developing toxicity.
Methods and Materials
Study population
This prospective cohort included 940 consecutive disease-free
women treated with RT for invasive breast cancer (Stage IeIII) or
ductal carcinoma in situ (DCIS), after breast-conserving surgery.
All patients were irradiated at the Department of Radiation
Oncology of the University Medical Center Groningen from
January 1, 2005 to June 1, 2010. During the study period, 3D-
CRT-SIB was the standard technique for postlumpectomy RT in
all invasive carcinoma and in patients with pure DCIS with an
indication for boost irradiation. Patients with a previous malig-
nancy, patients previously irradiated to the chest wall, and patients
treated with neoadjuvant chemotherapy were excluded.
The mean (SD) age was 58.7 (10.2) years at start of RT. The
majority of patients, 84.6%, had invasive breast cancer, of which
71.5% (n Z 672) had tumors 2 cm in diameter. Mean tumor
diameter was 16 (7.5) mm. Patient, tumor, and treatment-related
characteristics are summarized in Table 1.
Since April 2008, we subjected all new patients and all patients
previously treated in yearly follow-up to a standard follow-up
program, in which toxicity, quality of life, and tumor status were
prospectively scored and collected according to the hospital
institutional review board regulations. Median follow-up was 30
months (range, 6e54 months), with last follow-up set on
December 31, 2010.
Surgery
Primary surgery was performed in nine hospitals in the northern part
of The Netherlands. All patients were treated with lumpectomy. Incase of more than focally involved resection margins, re-resection
was performed (nZ 109; 11.6%) to achieve clear surgical margins.
Axillary staging was done with sentinel node biopsy (SN) in inva-
sive carcinoma. Axillary clearance, which followed positive results
on SN or positive cytology in the clinically node-positive axilla, was
performed in 283 patients (30.1%). In selected cases of pure DCIS,
an SN was carried out as well.
Radiotherapy
Radiotherapy was delivered with hypofractionated 3D-CRT-SIB,
as previously described by van der Laan et al. (3). Computed
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tion and a boost dose to the tumor bed area were given simulta-
neously. Two opposing tangential beams were directed to the
whole breast. In general, the boost plan consisted of three equally
weighted photon beams. The fractionation schemes used were 28
 1.8 Gy to the whole breast and a boost of 2.3 Gy (75.0%) or 2.4
Gy, resulting in a total dose of 64.4 or 67.2 Gy. The highest dose
was administered in case of focally positive resection margins.
These fractionation schedules are biologically equivalent to 25 
2 Gy with a sequential boost dose of 8  2 or 10  2 Gy using an
a/b of 10 for tumor control.
Regional RT (n Z 60; 6.4%), including irradiation of the
axillary, supra-, and infraclavicular nodal areas (and including the
internal mammary nodes in 7 cases), was applied in case of more
than three positive axillary lymph nodes or a positive apical lymph
node.
Systemic therapy
Adjuvant systemic therapy was indicated in patients with node-
positive disease and high-risk node-negative tumors. Patients were
classified as high risk depending on tumor size, grade, hormonal
receptor status, and age. In total, 338 women were treated with
chemotherapy, of whom 80.5% received 5-fluorouracil, epirubicine,
and cyclophosphamide (FEC). In 16.3% of the patients, FEC was
combined with taxane chemotherapy. In most patients with node-
positive disease, RT was given after completion of chemotherapy,
whereas in high-risk node-negative patients, RT was given before
chemotherapy. Hormonal therapy, tamoxifen, or aromatase inhibi-
tors, depending on menopausal status, were indicated for all
hormonal receptor-positive disease in the node-positive and high-
risk node-negative group. In patients receiving chemotherapy, tras-
tuzumab was indicated in tumors overexpressing human epidermal
growth factor receptor 2.
Toxicity assessment
After completion of RT, patients underwent routine yearly follow-up
to 5 years after RT. As of April 1, 2008, all patients were subjected to
the standard follow-up program. During follow-up, physician-rated
toxicity, according to Common Terminology Criteria for Adverse
Events version 3.0 (5), and CO were assessed. Cosmetic outcome
was scored according to a commonly used 4-point scale, ranging
from excellent to poor global cosmetic result, comparing the treated
with the untreated breast (6).
At 12, 24, 36, and 48 months, toxicity scores of 562, 515, 436,
and 200 patients were available, respectively, which corresponds
with an excellent compliance of >98% at all time points. Selected
endpoints were grade 2 fibrosis in the boost area, any-grade
fibrosis in the non-boost area, grade 2 telangiectasia, any-grade
breast edema, any-grade pain to the chest wall, any-grade rib
fracture, and fair/poor CO.
Statistical analysis
Follow-up time was calculated as the interval between date of
completion of RT and last follow-up visit. Prevalence of toxicities
and corresponding 95% confidence intervals were presented at
different time points: 12 (6, <18), 24 (18, <30), 36 (30,
<42), and 48 (42, <54) months.Multivariate logistic regression analyses, with forward selection
and extended bootstrapping technique as described by Beetz et al.
(7), were performed to study the influence of clinicopathologic
factors on toxicity and CO. Fibrosis in the boost area, fibrosis in the
non-boost area, telangiectasia, and CO were evaluated at 36 months
of follow-up. Evaluation of breast edema and pain to the chest was
chosen at 12 months because of an observed decrease over time.
Because of the low number of observed rib fractures, no analysis was
performed for this endpoint. The following covariates were consid-
ered: age at start ofRT (50/>50years); re-resection (no/yes); tumor
location (lateral/medial/other); pathologic tumor size (continuous in
millimeters); axillary clearance (no/yes); chemotherapy combined
with sequence of treatment (surgery-RT/chemotherapy-RT/RT-
chemotherapy); hormonal therapy (no/yes); trastuzumab (no/yes);
regional RT (no/yes); boost dose tumor bed (low/high); and smoking
(no/yes, defined as smoking during RT).
The analyses for model building were performed in MATLAB
(version R2009b; MathWorks, Natick, MA) and were repeated in
SPSS version 16.0 (SPSS, Chicago, IL) to calculate odds ratios. A
p value 0.05 was considered statistically significant.
Results
Toxicity outcomes
Grading of toxicities is presented in Fig, with number of events
listed in Table 2. Comparing the prevalence of events at every time
point, grade 2 fibrosis in the boost area seemed stable over time.
Prevalence of grade 2 fibrosis to the boost area ranged from
10.4% at 12 months to 6.6% at 48 months of follow-up. This
stability over time could also be observed in fibrosis outside the
boost area. At 36 months, the prevalence of any-grade fibrosis in
the non-boost area was highest (49.5%). Telangiectasia was
observed infrequently, with grade 2 telangiectasia of 3.7% at 36
months. Both breast edema and mild or worse pain to the chest
wall gradually decreased over time, with a decrease in breast
edema from 26.2% at 12 months after completion of RT to 6.1% at
48 months. Pain of the chest wall decreased from 12.2% to 7.5%.
Overall, seven rib fractures (0.7%) were reported. Physician-rated
CO seemed fairly stable over time. At 48 months, 64.1% of
patients had a good or excellent CO.
Multivariate regression analyses
Results of the multivariate regression analysis are shown in
Table 3. Sequencing chemotherapy after RT was the only signif-
icant factor associated with grade 2 fibrosis in the boost area,
compared with no chemotherapy at 36 months of follow-up.
Comparing chemotherapy before or after RT, an increased risk
of grade 2 fibrosis in the boost area in patients who received
chemotherapy after RT was observed (odds ratio 4.9, 95% confi-
dence interval 1.5e16.1, p Z 0.008). The presence of fibrosis in
the non-boost area at 3 years was significantly associated with
both larger tumor size and the performance of a re-resection. No
significant risk factors could be identified for grade 2 telangi-
ectasia. Breast edema at 12 months was seen more frequently after
axillary clearance and in patients with larger tumors. Pain to the
chest wall was the only endpoint to which age was associated. At
12 months, a significant 2.4-fold higher risk of pain to the chest
wall was observed in younger patients (50 years) and a 2.1-fold
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Fig. Cross-sectional physician-rated toxicity: (A) fibrosis boost area, (B) fibrosis non-boost area, (C) telangiectasia, (D) edema breast, (E)
pain chest wall, (F) rib fracture, and (G) cosmetic outcome, described in proportions of patients at different time points (12, 24, 36, and 48
months after radiotherapy) in women treated with three-dimensional conformal radiotherapy with a hypofractionated, simultaneous inte-
grated boost after breast-conserving surgery.
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resection the risk of a fair or poor CO was increased by four-
fold. Furthermore, larger tumors and regional RT were significant
prognostic factors for worse CO.
Discussion
In this article we present the first results on toxicity in breast cancer
patients treated with the 3D-CRT-SIB technique. In general,
physician-rated toxicity was not impaired and was comparable to
the known literature, with a prevalence of grade 2 fibrosis in the
boost area of 8.5% at 3 years after RT. Patients treated with a high
boost dosage were more at risk of developing pain to the chest wall.For fibrosis, similar results have been previously reported, with
grade 2 fibrosis in the boost area or the operation site ranging
from 7.2% to 26.8%. These patients were treated with breast-
conserving surgery combined with whole-breast irradiation with
or without a boost (8, 9). Although in the higher range, the rated
fibrosis in the whole breast in our series, defined as the area
outside the boost, corresponds with publications of others, ranging
from 32.7% to 48.2% (8e11).
When using 3D-CRT-SIB, a higher dose per fraction is delivered
to the boost area, which may result in an increased risk of fibrosis in
this area. On the other hand, less excessive dose is delivered outside
the boost area (3), possibly resulting in less fibrosis in the remaining
breast. Furthermore, with the current knowledge on the a/b for
tumor control of 4.6 (12), the chosen hypofractionated regimen in
Table 2 Number of events at different times of follow-up
Endpoint
Time since completion of radiotherapy (no. of toxicity scores available)
12 mo (562) 24 mo (515) 36 mo (436) 48 mo (200)
n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Grade 2 fibrosis boost area 58 10.4 7.8, 12.9 44 8.6 6.1, 11.0 37 8.5 5.9, 11.1 13 6.6 3.1, 10.0
Fibrosis non-boost area 269 47.9 43.7, 52.0 224 43.9 39.6, 48.2 215 49.4 44.7, 54.1 74 37.4 30.6, 44.1
Grade 2 telangiectasia 6 1.1 0.2, 1.9 15 2.9 1.5, 4.4 16 3.7 1.9, 5.5 7 3.5 1.0, 6.1
Edema breast 147 26.2 22.5, 29.8 69 13.5 10.5, 16.4 48 11.0 8.1, 14.0 12 6.1 2.7, 9.4
Pain chest wall 68 12.2 9.5, 14.9 36 7.0 4.8, 9.2 29 6.7 4.3, 9.0 15 7.5 3.9, 11.2
Rib fracture 1 0.2 0.2, 0.5 4 0.8 0.02, 1.5 1 0.2 0.2, 0.7 1 0.5 0.5, 1.5
Cosmetic outcome fair or poor 191 34.0 30.1, 37.9 181 35.4 31.3, 39.6 172 39.7 35.1, 44.3 71 35.9 29.2, 42.5
Abbreviation: CI Z confidence interval.
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with the sequential boost technique.
In our series, fibrosis, either in the boost or in the non-boost area,
is not increased compared with the known literature. However,
patients treated with chemotherapy sequentially to RT had an
elevated risk of developing fibrosis in the boost area, compared with
patients without chemotherapy. In patients receiving chemotherapy,
RT before chemotherapy had an almost fivefold increased risk for
the development of grade2 fibrosis compared with chemotherapy
first. This latter effect might be partly explained by the longer
interval between surgery and RT. In all patients treated with
chemotherapy before RT this interval exceeded 4 months (data not
shown). Another explanationmight be that the increased fibrosiswas
secondary to a radiation recall reaction after chemotherapy. WeTable 3 Multivariate logistic regression models of toxicity
Dependent variable Predicto
Grade 2 fibrosis boost at 36 mo (n Z 426) Treatment
Surgery
Chemot
RT-chem
Fibrosis non-boost at 36 mo (n Z 425) Tumor siz
Re-resecti
No
Yes
Edema breast at 12 mo (n Z 535) Axillary c
No
Yes
Tumor siz
Pain chest wall at 12 mo (n Z 532) Age at sta
50
>50
Boost dos
Low (6
High (6
Fair/poor cosmetic outcome at 36 mo (n Z 423) Re-resecti
No
Yes
Tumor siz
Regional R
No
Yes
Abbreviations: OR Z odds ratio; CI Z confidence interval; RT Z radiothecould not confirm this in our series, because unexpected skin reac-
tions after chemotherapywere not assessed in the standard follow-up
program. Furthermore, several studies, mainly using cyclophos-
phamide,methotrexate, and 5-fluorouracil (CMF) showed a negative
effect of chemotherapy on the development of fibrosis (11, 13, 14).
However, none of these studies specifically compared chemotherapy
followed by RTwith RT before chemotherapy and compared mainly
with concurrent chemotherapy and RT. Although the sequences of
chemotherapy and RT were considered as separate covariates,
Collette et al. (13) found that chemotherapy during RT increased the
10-year risk of fibrosis in the boost area. In our series, chemotherapy
was not given concurrently with RT.
We observed an increased risk of fibrosis outside the boost area
with increasing tumor size and after re-resection. This is the onlyr variable OR 95% CI p
sequence 0.008
-RT 1
herapy-RT 0.57 0.19, 1.69 0.31
otherapy 2.78 1.29, 6.00 0.009
e (mm) 1.06 1.03, 1.09 <0.001
on
1
2.19 1.19, 4.03 0.012
learance
1
2.81 1.83, 4.32 <0.001
e (mm) 1.04 1.01, 1.07 0.004
rt RT (y)
1
0.41 0.23, 0.72 0.002
age
4.4 Gy) 1
7.2 Gy) 2.06 1.16, 3.67 0.01
on
1
4.52 2.42, 8.45 <0.001
e (mm) 1.05 1.02, 1.08 0.001
T
1
2.89 1.17, 7.14 0.02
rapy.
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of fibrosis. No RT-associated predictors were correlated with the
development of fibrosis, either in the non-boost or the boost area.
Telangiectasia grade2 was observed in 48 patients (3.7%) at 3
years of follow-up. The reported incidence of telangiectasia ranges
from 3.1% to 32.1% (9e11). Lilla et al. (9), who found telangi-
ectasia in 32.1%, identified several factors, such as older age,
higher normalized tissue dose, and acute skin toxicity, related to the
presence of telangiectasia. Another factor related to telangiectasia
is systemic therapy with CMF (14). We did not identify any
significant prognostic factors for the development of telangiectasia.
The prevalence of breast edema and pain to the chest wall
decreased over time, suggesting transient effects. Edema of the
breast has been described as occurring in 2.5%e17.7% of women
undergoing breast irradiation after breast-conserving surgery
(9e11, 15). These results are comparable to those found in the
present series.
Pain at the chest wall, specifically after BCT, has been inves-
tigated to a limited degree. We identified only one study reporting
chest wall pain after breast cancer surgery (16). This study
reported that 25.1% of 3253 patients complained of chest wall
pain at 26 months (median) after surgery. No differences in
prevalence of pain were found according to type of surgery (BCT
or mastectomy) (16). In the present study, 1 year after RT, risk of
pain to the chest wall was doubled in patients treated with high
boost dosage, with an absolute increase from 10.2% in the low
boost group to 18.9% in the high boost dosage group. This finding
might reflect a doseeeffect relationship of the dose to the ribs,
connective tissue, and muscles.
Young age (50 years) only had impact on the presence of
pain to the chest wall 1 year after irradiation. Younger patients had
more pain complaints and used more pain medication. Similar
results were previously found in a nationwide Danish survey study
(17), in which younger age was associated with the development
of chronic pain after breast cancer treatment. In this survey, this
age-related finding was explained by the misattribution of pain
and the decreased tendency to label a sensation as painful with
increasing age (16). Rib fractures were observed infrequently,
with seven events (0.7%). This number is consistent with other
series, reporting 0.3%e2.2% rib fractures after BCT (18).
Cosmetic outcome can be considered as the end result of all
breast-related toxicities and is known to impact quality of life. In
our series, the physician-rated fair to poor CO was 39.7% at 3 year
of follow-up. In the literature, a wide variety of scores have been
reported, from 21% to 45% (10, 15, 19). The wide range of scores
can be partly explained by differences in the use of evaluation
instruments for CO. We used the 4-point scale from Harris (6),
which is easy in routine use, with only a modest reduction of
interrater reliability compared with multi-item scales (20).
However, it is shown that a single evaluator instead of a panel
assessment may impair reliability (20).
Numerous factors have been identified as impacting CO after
BCT (10, 14, 15, 19). We identified the performance of a re-
resection as the most important predictor for a fair to poor CO.
Although investigated as a candidate risk factor in other studies
(15, 19), only Hau et al. (15), in a recent analysis on panel-rated
CO, reported re-resection as a predictor for poor CO. In our series,
increasing pathologic tumor size was associated with poor CO.
Volume differences and deformation between the two breasts are
the most important factors in the physicians’ assessment of global
CO. These volume differences are caused by the performance of
a re-resection, and larger tumors result in larger excised volumes.The prospective data collection and the large number of
patients included, combined with multiple measurements over
time, are unique for this study. However, one limitation is the
relatively short follow-up time, given that complications of RT can
be present more than 10 years after treatment (17). Furthermore,
in our study we were not able to consider large breast size, a factor
that could negatively influence toxicity (10, 19).
In conclusion, the hypofractionated 3D-CRT-SIB technique as
part of BCT is safe regarding normal tissue complications.
Fibrosis in the boost area was not associated with RT parameters.
Cosmetic outcome was influenced most by the performance of
a re-resection. Furthermore, young age was found to be prognostic
for the risk of pain to the chest wall.References
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